<SEC-DOCUMENT>0001213900-20-011394.txt : 20200508
<SEC-HEADER>0001213900-20-011394.hdr.sgml : 20200508
<ACCEPTANCE-DATETIME>20200508113030
ACCESSION NUMBER:		0001213900-20-011394
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20200507
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200508
DATE AS OF CHANGE:		20200508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		20859389

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea121560-8k_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549<BR>
____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934<BR>
<BR>
</B>Date of Report (Date of earliest event reported): May 7, 2020<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><U>Nevada</U></TD>
    <TD STYLE="width: 34%; text-align: center"><U>001-38543</U></TD>
    <TD STYLE="width: 33%; text-align: center"><U>26-1265381</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; text-align: center"><U>400 Water Street, Suite 200, Rochester, MI</U></TD>
    <TD STYLE="width: 30%; text-align: center"><U>48307</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center"><B>Trading symbol</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">OPRX</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nasdaq Capital Market</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 7, 2020, we issued a press release announcing that our chief
commercial officer, Steve Silvestro, has been honored with the 2020 PM360 ELITE 100 Award for his organizational leadership and
positive impact on the healthcare industry. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR>                                                                                                                                                                                                                                                                                                                                                                                    <TR STYLE="vertical-align: top">
<TD></TD><TD></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD>99.1</TD><TD><A HREF="ea121560ex99-1_optimizerx.htm" STYLE="-sec-extract: exhibit">Press release, dated May 7, 2020</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Douglas Baker</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Douglas Baker<BR>
Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date May 8, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea121560ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED MAY 7, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 8pt 22.5pt; text-align: center"><IMG SRC="image_001.gif" ALT="" STYLE="height: 51px; width: 219px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OptimizeRx&rsquo;s Steve Silvestro Honored
as Transformational Leader in Healthcare by PM360</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ROCHESTER, Mich. &ndash; May 7, 2020 &ndash; </B><FONT STYLE="color: Black"><U>OptimizeRx
Corp.</U> (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, announced its
chief commercial officer, Ste</FONT>ve Silvestro, has been <U>honored</U> with the <U>2020 PM360 ELITE 100</U> Award for his organizational
leadership and positive impact on the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1.5in">&nbsp;<IMG SRC="image_003.gif" ALT=""></TD>
    <TD>The annual awards program recognizes the 100 most influential people in the healthcare industry as the ELITE, which stand
    for Exceptional Leaders, Innovators, Transformers, and Entrepreneurs. The award is sponsored by <U>PM360</U>, the premier
    magazine and online news source for marketing decision makers in the pharmaceutical, biotech, and medical device industries.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;<IMG SRC="image_002.gif" ALT=""></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">PM360 received hundreds of nominations which were evaluated and
selected by the PM360 editorial staff based on accomplishments, testimonials, and supporting evidence that reflected the impact
of their efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Silvestro was recognized in the Transformational Leaders category
for his exceptional ability to foster positive organizational change, with his <U>profile</U> featured on the <U>PM360 ELITE 100
</U>website and in the publication&rsquo;s <U>May 2020 issue</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;This well-deserved award reflects Steve&rsquo;s career-long
commitment to improving outcomes for all stakeholders in healthcare, from patient and doctors, to organizations that provide life-saving
medications and treatments,&rdquo; commented OptimizeRx CEO, William Febbo. &ldquo;Steve has become a trusted advisor to our clients
on key strategic initiatives, a mentor among his peers, and a valuable member of our executive team. He has earned deep respect
within our organization for his transformational work that has driven the growth and market expansion of our OptimizeRx digital
health platform and our ability to deliver the best in connected care.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">CEO and publisher of PM360, Anna Stashower, stated: &ldquo;At a
time when the world is being impacted by a healthcare crisis in the COVID-19 pandemic, it is nice to be able to reflect on the
extraordinary work those in the life sciences do to discover, develop, and promote life-saving treatments. Our ELITE winners epitomize
the very best of our industry. We are incredibly thankful for everything they do and proud to honor all of their achievements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">See Steve Silvestro&rsquo;s PM360 ELITE 100 profile <U>here</U>,
and more information about the PM360 ELITE 100 Award at <U>pm360online.com/the-2020-pm360-elite-100</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>About OptimizeRx</B><FONT STYLE="font-size: 10pt">&reg;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">OptimizeRx Corporation (NASDAQ: OPRX)
is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused
on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence
and care management. OptimizeRx&rsquo;s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support
on specialty medications and patient financial assistance directly within a provider&rsquo;s workflow through leading electronic
health platforms. OptimizeRx&rsquo;s fully integrated platform supports the real-time exchange of information, improving provider
knowledge and patient engagement, and ultimately leading to healthier outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">For more information, follow the company
on <U>Twitter</U>, <U>LinkedIn</U> or visit <U>www.OptimizeRx.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Important Cautions Regarding Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">This press release contains forward-looking
statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities
Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,'
'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement
was m</FONT>ade. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because
of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth
in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements
are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>OptimizeRx Contact </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Doug Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (248) 651-6568 x807</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>dbaker@optimizerx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Media Relations Contact </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Maira Alejandra, Media Relations Manager</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (754) 245-7070</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>malejandra@optimizerx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>Investor Relations Contact </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Ron Both, CMA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Tel (949) 432-7557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"><U>oprx@cma.team</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #0563C1"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=AVP S '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M&J1-W ;5 1_YVV7AQHE1)T\-KG$"9)"%E2Q6NW?#RP,.!/Z8[,"ZA!$.4/]
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MU+U@EQ#Z'"!]%OO+M;)F%):9!ADM:@U[V), 9:&F,3!3!P4&X(].'>U)PJC
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.gif
M1TE&.#=A3 !9 '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M0V><P*XJZG8H^GBN^Y',^PDG+AP^Y+<_@7\&C2!ITP^<<)"=!F4PP$ &!F3
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M(()8DFZF)*5K)BFG0 VT )H,$1):((P1%ABAJ0::LYT!&)31;Z XZLJ="!U
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M!%CRDD>4I1]/J$(CH@]Y%\@2-@VV2,,=S20?(%4&+J#_S(4TLYGC(R-:$(A
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M*Z#.]>R[B^:XJPP?.I,:_M>AW@4!DF0ZTTT,Y_;I$@/_X\ #QKWSJ_)Z .!
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M#2-F>,2H'9&W&RKQ$BLQ%BHQ@;<H%D6134E#6++X#G @ .2 !W*  "V$ 4%
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MR0 'H.  PIF>I&";NBD9+4$6XT * 3J@):D  @JCG5D [T"9)2&?(^ -2 I
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MF;,V#HLIEYYZKMLXH..@J*W:CW+9G@IPIC_JCZ[ZK&Y:$IX!4R'60+G*%VC
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+H9N=Z'JJ A 0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
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5-%DGIJ1)'S%2";Y8J;(E2Q,A   [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
